Format

Send to

Choose Destination
Acta Clin Belg. 2018 Jul 23:1-10. doi: 10.1080/17843286.2018.1494669. [Epub ahead of print]

2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients.

Author information

1
a Immunodeficiency Treatment Unit, Hôpital Erasme , Université Libre de Bruxelles (U.L.B.) , Brussels , Belgium.
2
b Laboratory of Vaccinology and Mucosal Immunity , Université Libre de Bruxelles (U.L.B.) , Brussels , Belgium.
3
c Fonds des Affections Respiratoires(FARES) , Belgium.
4
d Belgian Lung and Tuberculosis Association (BELTA) , Belgium.
5
e Dept of General Internal Medicine , University Hospital Ghent , Ghent , Belgium.
6
f Immunobiology Unit, Hôpital Erasme , Université Libre de Bruxelles (U.L.B) , Brussels , Belgium.

Abstract

OBJECTIVES:

To review the current knowledge on screening for latent tuberculosis infection (LTBI) in HIV-infected adults and provide specific guidelines for Belgium. Focus is given to who to test, which testing method to use, timing of screening and choice of LTBI treatment.

METHODS:

Expert review by the members of the Belgian LTBI group, in consultancy with the ARC College.

RESULTS:

Target population, timing of screening, testing method, active TB exclusion, treatment of LTBI and guideline implementation are all reviewed.

CONCLUSIONS:

The principal changes include a selective approach to screen for LTBI (screening only of the HIV-infected patients at highest risk of active TB) as well as the timing of screening (testing for LTBI performed only after immune-restauration by antiretroviral therapy).

KEYWORDS:

HIV; Interferon-gamma release assay.; Latent tuberculosis; Screening; Tuberculin skin test

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center